# Seraseal for Endoscopic Hemostasis

> **NCT02349490** · PHASE4 · COMPLETED · sponsor: **Medical University of Vienna** · enrollment: 37 (actual)

## Conditions studied

- Gastrointestinal Hemorrhage

## Interventions

- **DEVICE:** Seraseal / Fastact Hemostatic agent (combined activated factors IIa, VIIa, IXa, Xa )

## Key facts

- **NCT ID:** NCT02349490
- **Lead sponsor:** Medical University of Vienna
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-11
- **Primary completion:** 2013-07
- **Final completion:** 2015-01
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2015-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02349490

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02349490, "Seraseal for Endoscopic Hemostasis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02349490. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*